NanoScreen Transitions From Partnership to Corporation
News Mar 17, 2016
NanoScreen has announced that it has updated its corporate structure to better position itself for growth. Formerly known as Nanoscreen, LLC, the company is now NanoScreen, Inc. This change re ects the Company's commitment, knowledge and expertise in driving the growth needed to accelerate the future of the Life Sciences industry.
NanoScreen also announced a partnership with Advanced Precision Medicine, Inc., a local molecular diagnostics lab, to help revolutionize traditional medical practices through a suite of molecular diagnostics tests. "It is rewarding to see two technology companies connect and partner up to become leaders of integrated healthcare solutions," said Ernest Andrade, Executive Director of the Charleston Digital Corridor. "This is a prime example of community and talent coming together to grow our Life Sciences community."
"The changes we have made provide us with the exibility to serve new markets and expand our product portfolio. Our commitment to transform the modern Life Sciences laboratory remains unchanged. NanoScreen will continue to build its momentum by securing new capital and embarking on a new growth phase for the company," said Garey De Angelis, Chairman of NanoScreen.
"NanoScreen products and technologies have served as the backbone for research-advancing precision medicine applications since the completion of the Human Genome project." said Dean Sproles, newly appointed Chief Executive Officer of NanoScreen. "Launching the ORION automated liquid handling workstation will transform and accelerate biomarker discovery and laboratory automation initiatives around the globe."
The new name is effective immediately, and will be implemented across the company's products and services throughout the 2016 calendar year.
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE